The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

However, upon its commercial launch, Enflonsia is likely to face stiff competition from AstraZeneca AZN / Sanofi ’s SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023 ...

Enflonsia joins a short list of new tools to prevent RSV in infants. Another RSV antibody called Beyfortus, made by Sanofi and AstraZeneca, was approved in 2023. But there were supply shortages during ...

BofA Securities lowered its price target on Sanofi (SAN:FP) (NASDAQ: SNY) to EUR8.40 from EUR8.48 on Tuesday, while maintaining a Buy rating on the French pharmaceutical company’s stock. With a ...

Another RSV antibody called Beyfortus, made by Sanofi and AstraZeneca, was approved in 2023. But there were supply shortages during last year’s RSV season.

SUMMARY: The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEYFORTUS and is publishing this notice of that determination as required by law. FDA has ...

This document is unpublished. It is scheduled to be published on 06/16/2025. Once it is published it will be available on this page in an official form. Until then, you can download the unpublished ...

BioWorld Content on 'Astrazeneca plc'With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and ...